NASDAQ:STOK

Stoke Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy STOK

*Your capital is at risk

$28.86

-1.18 (-3.93%)

At Close: Jul 31, 2026

Stoke Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 7.48. In total, the insiders bought 1.57M and sold 268.45K STOK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	7.48
● Buy	1.57M shares
● Sell	268.45K shares
55% Buy Activity Strong Positive Correlation
Buy Signal Medium Confidence Jul 15, 2026 Analysis Breakdown: Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 17, 2026 Sell	Common Stock S-Sale	Allan Jonathan General Counsel & Corp Sec	Officer	1 791 Value: $59.8K
Mar 17, 2026 Sell	Common Stock S-Sale	Hoitt Jason Chief Patient Officer	Officer	1 033 Value: $33.8K
Mar 17, 2026 Sell	Common Stock S-Sale	Hoitt Jason Chief Patient Officer	Officer	748 Value: $25.0K
Mar 17, 2026 Sell	Common Stock S-Sale	Allan Jonathan General Counsel & Corp Sec	Officer	2 476 Value: $81.1K
Mar 17, 2026 Sell	Common Stock S-Sale	Ticho Barry Chief Medical Officer	Officer	3 577 Value: $117.1K
Mar 17, 2026 Sell	Common Stock S-Sale	Ticho Barry Chief Medical Officer	Officer	2 587 Value: $86.3K
Mar 17, 2026 Sell	Common Stock S-Sale	Leggett Thomas Chief Financial Officer	C-Suite Officer	1 274 Value: $41.7K
Mar 17, 2026 Sell	Common Stock S-Sale	Leggett Thomas Chief Financial Officer	C-Suite Officer	922 Value: $30.8K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Allan Jonathan General Counsel & Corp Sec	Officer	7 475 Value: $215.7K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Allan Jonathan General Counsel & Corp Sec	Officer	6 000 Value: $173.2K
Mar 15, 2026 Buy	Common Stock M-Exempt	Allan Jonathan General Counsel & Corp Sec	Officer	7 475 Value: $215.7K
Mar 15, 2026 Buy	Common Stock M-Exempt	Allan Jonathan General Counsel & Corp Sec	Officer	6 000 Value: $173.2K
Mar 15, 2026 Buy	Common Stock M-Exempt	Allan Jonathan General Counsel & Corp Sec	Officer	12 000 Value: $346.3K
Mar 15, 2026 Buy	Common Stock M-Exempt	Kaye Edward M. Md Director	Director	35 500 Value: $1.02M
Mar 15, 2026 Buy	Common Stock M-Exempt	Kaye Edward M. Md Director	Director	26 250 Value: $757.6K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Ticho Barry Chief Medical Officer	Officer	10 750 Value: $310.2K
Mar 15, 2026 Buy	Common Stock M-Exempt	Ticho Barry Chief Medical Officer	Officer	13 100 Value: $378.1K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Hoitt Jason Chief Patient Officer	Officer	10 000 Value: $288.6K
Mar 15, 2026 Buy	Common Stock M-Exempt	Hoitt Jason Chief Patient Officer	Officer	10 000 Value: $288.6K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Leggett Thomas Chief Financial Officer	C-Suite Officer	14 750 Value: $425.7K
Mar 15, 2026 Buy	Common Stock M-Exempt	Leggett Thomas Chief Financial Officer	C-Suite Officer	14 750 Value: $425.7K
Mar 15, 2026 Buy	Common Stock M-Exempt	Ticho Barry Chief Medical Officer	Officer	10 750 Value: $310.2K
Mar 15, 2026 Buy	Common Stock M-Exempt	Ticho Barry Chief Medical Officer	Officer	10 000 Value: $288.6K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Ticho Barry Chief Medical Officer	Officer	10 000 Value: $288.6K
Mar 15, 2026 Buy	Restricted Stock Units M-Exempt	Ticho Barry Chief Medical Officer	Officer	13 100 Value: $378.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT STOKE THERAPEUTICS, INC.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome,...

Read Full Profile Here